Skip to main content
Home ESG Stocks
Agilent Technologies, Inc. (A) Stock Analysis & ESG Ratings
A

Agilent Technologies, Inc.

Market Price
$329.16
24h Change
+2.10%
Market Cap
$15.76B
P/E Ratio
N/A

ESG & Sustainability Rating Breakdown

Synthesized multi-provider rating across Environmental, Social, and Corporate Governance dimensions.

Audited Methodology

MSCI ESG Rating

69.1 / 100

MSCI ESG industry rating benchmark.

Sustainalytics Risk Score

N/A

Sustainability Strengths & Catalysts (Pros)

  • Undervalued with Strong Growth: Trading 30.9% below fair value with analyst consensus targeting 26.1% upside, while earnings forecast to grow 9.26% annually supported by pharmaceutical and diagnostics market expansion.
  • Exceptional Dividend Growth: Nine consecutive years of dividend increases with 7.80% five-year CAGR, conservative 18.19% payout ratio, and 4.7x coverage ratio ensuring sustainable income growth.
  • Market Leadership and Innovation: Leading position in $60 billion lab instruments market growing at 6% CAGR, with AI-driven diagnostics and sustainable lab tools driving competitive advantages.

Material Risks & Governance Concerns (Cons)

  • Low Dividend Yield: Current 0.85% yield significantly trails market averages, limiting immediate income appeal for dividend-focused investors despite strong growth trajectory.
  • Revenue Growth Headwinds: Q1 2025 revenue declined slightly year-over-year to $1.68 billion, indicating potential market saturation or competitive pressures in core segments.

Company Profile & Business Model Overview

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer’s representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.

Financial & Valuation Fundamentals

Earnings Per Share (EPS)
$16.51
Dividend Yield
0.87%
Previous Close
$323.77
Day Open
$328.08

Data Integrity & Methodology Disclosure

Stock prices and market fundamentals are refreshed via our automated 04:00 UTC pipeline. ESG evaluations aggregate published ratings from MSCI ESG Research and Sustainalytics with normalized industry peer adjustments. Learn more in our ESG Rating Methodology.